Phase I dose-escalation study of oral administration of MET Tyrosine Kinase Inhibitor S 49076 in patients with advanced solid tumours

Trial Profile

Phase I dose-escalation study of oral administration of MET Tyrosine Kinase Inhibitor S 49076 in patients with advanced solid tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs S-49076 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Servier
  • Most Recent Events

    • 01 Aug 2017 Results published in the European Journal of Cancer.
    • 01 Nov 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 23 Oct 2013 Interim results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top